Ankylosing Spondylitis: Pathophysiology and Treatment
This paper provides a structured overview of ankylosing spondylitis (AS), a chronic inflammatory condition primarily affecting young males and characterized by progressive spinal fusion. It examines the disease's largely unknown etiology, its association with the HLA-B27 gene, and its relatively low prevalence in the general population. The paper describes the pathophysiology of AS — including inflammation at the bone-cartilage interface, the role of TNF-alpha, and mechanisms of bone resorption and new bone formation — before outlining the clinical manifestations that arise from these processes. It concludes with a review of pharmacological treatments, including NSAIDs and biologic agents, and emphasizes the importance of early intervention and patient education.
- Introduction: Definition and overview of ankylosing spondylitis
- Etiology and Incidence: HLA-B27 gene link and population prevalence data
- Pathophysiology: Inflammation, bone resorption, and TNF-alpha mechanisms
- Clinical Manifestations Related to Pathophysiology: Spinal, joint, and extraarticular symptom patterns
- Pharmacological Treatments: NSAIDs, biologics, and surgical considerations
- Critical Thinking: Long-term care, early treatment, and patient education
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Follows a logical clinical structure — moving from etiology through pathophysiology to manifestations and treatment — which mirrors the standard approach used in medical case reviews.
- Connects pathophysiological mechanisms directly to observable clinical symptoms, helping the reader understand why specific manifestations occur.
- Draws on multiple peer-reviewed sources to support each section, giving the paper appropriate academic grounding for an undergraduate health sciences course.
Key academic technique demonstrated
The paper demonstrates disease-based integrative analysis: rather than treating etiology, pathophysiology, and treatment as isolated topics, it threads them together causally. For example, the discussion of TNF-alpha and Wnt upregulation in the pathophysiology section is linked forward to the rationale for TNF-inhibitor drug therapy, showing that treatment choices follow mechanistic logic.
Structure breakdown
The paper opens with a brief definition of the disease, then proceeds through six sections: a general introduction, etiology and epidemiology, pathophysiology, clinical manifestations, pharmacological treatments, and a critical-thinking reflection on long-term patient care. The reflection section is brief but adds value by addressing the practitioner's role and the importance of patient education — a common expectation in nursing and allied health writing assignments.
Introduction
Ankylosing spondylitis is a chronic inflammatory condition that primarily affects young males and may lead to fusion of the spine (Sarker, 2016). This fusion can cause the spine to become rigid, leading the patient to develop a hunched back. As a result, the patient may experience breathing problems due to the altered posture. Other inflammatory signs may also appear in various parts of the body, such as the eyes (Sieper & Braun, 2010).
Etiology and Incidence
The etiology of ankylosing spondylitis remains largely unknown, though there are indications of a genetic risk component. Researchers have highlighted its association with the HLA-B27 gene. Several immunological mechanisms have been proposed, but they appear less clearly defined than those seen in reactive arthritis.
The prevalence of ankylosing spondylitis in the general population is low, ranging from 0.1% to 1.4%. It is more prevalent among Caucasians than among members of other racial groups, and those suffering from chronic lower back pain are more vulnerable to the disease. Among North American Caucasians, the HLA-B27 gene occurs in approximately 7% of the general population and in greater than 90% of those with ankylosing spondylitis (Gaidukova & Rebrov, 2016). Individuals who carry HLA-B27 have up to a 6% chance of developing the condition. Although the disease had previously been thought to affect primarily males, more recent studies indicate that women are also affected, with a female-to-male ratio of approximately 1:3. The mean age of onset is 23 years (Moon & Kim, 2014).
References
Ebringer, A., & Ebringer, A. (2012). Muscle changes in ankylosing spondylitis. Ankylosing Spondylitis and Klebsiella, 45–50. doi:10.1007/978-1-4471-4300-0_6
Gaidukova, I. Z., & Rebrov, A. P. (2016). The risk of coronary artery disease development in patients with ankylosing spondylitis (Bechterew's disease) and psoriatic arthritis: A 10-year prospective follow-up study. The Clinician, 10(3), 26–31. doi:10.17650/1818-8338-2016-10-3-26-31
Moon, K., & Kim, Y. (2014). Medical treatment of ankylosing spondylitis. Hip & Pelvis, 26(3), 129. doi:10.5371/hp.2014.26.3.129
Sarker, H. (2016). Case-45 back pain and stiffness (ankylosing spondylitis). Short & Long Cases in Clinical Medicine, 354–357. doi:10.5005/jp/books/12920_46
Shin, K. (2013). Clinical manifestation and diagnosis of ankylosing spondylitis. Korean Journal of Medicine, 85(3), 240. doi:10.3904/kjm.2013.85.3.240
Sieper, J., & Braun, J. (2010). Management of ankylosing spondylitis. Ankylosing Spondylitis, 49–72. doi:10.1007/978-0-85729-180-6_6
Tsai, W. (2012). HLA-B27 and ankylosing spondylitis. Clinical and Molecular Advances in Ankylosing Spondylitis. doi:10.5772/30113
Wolf, J. (2012). Clinical features of ankylosing spondylitis. Clinical and Molecular Advances in Ankylosing Spondylitis. doi:10.5772/29655
Already a member? Log in
Unlock the rest of this paper
135,000+ research papers · AI writing tools · Plagiarism & AI detection
7-Day Pass
Does not renew
Get 7-Day PassMonthly
Renews at $12.99/month until canceled
Start MonthlyAnnual
Renews at $99/year until canceled
Start Annual- Unlimited AI writing tools
- Plagiarism and AI text detection tool
Plan details
Unlimited AI writing tools are for individual, non-automated use and are subject to our Terms of Service and abuse-prevention measures.
TextChecker scans: 3 during the 7-Day Pass, or 5 per month with Monthly and Annual.
Prices exclude applicable tax.
Always verify citation format against your institution’s current style guide requirements.